PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ibrexafungerp→

Ibrexafungerp PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1207753-03-4
Molecular formula
C44H67N5O4
Molecular weight
730.05 g/mol
Drug class
Oral triterpenoid antifungalfungal 1,3-beta-D-glucan synthase inhibitor
Mechanism of action
Inhibits fungal 1,3-beta-D-glucan synthase, disrupting synthesis of an essential component of the fungal cell wall and causing structural instability and cell death.
Indications / reported uses
  • Treatment of vulvovaginal candidiasis (VVC) in adult and postmenarchal paediatric patients
  • Reduction in the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal paediatric patients after treatment of the current episode; regimen and indication are product-label specific

Sources: US DailyMed — BREXAFEMME (ibrexafungerp) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ibrexafungerp PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ibrexafungerp Permitted Daily Exposure (PDE) report (the Ibrexafungerp PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ibrexafungerp Occupational Exposure Limit (OEL) report (the Ibrexafungerp OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.